CAPR

Business Context and Reporting Period

Company: Nile Therapeutics, Inc. (a development-stage biopharmaceutical company)

Reporting Period: Quarterly period ended March 31, 2009 (Form 10-Q)

Business Overview: Nile Therapeutics focuses on developing innovative products for cardiovascular diseases. Its lead compound, CD-NP, is a chimeric natriuretic peptide in Phase II clinical studies for heart failure. A second candidate, CU-NP, is in pre-clinical development. The company terminated its 2NTX-99 program in early 2009 to concentrate resources on its natriuretic peptide franchise.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by approximately $1.39 million (44%) from $3.18 million in Q1 2008 to $1.79 million in Q1 2009.
• Research and Development (R&D): R&D expenses declined by approximately $654,000 (33%) to $1.32 million. This reduction was driven by a $488,000 decrease in manufacturing expenses (CD-NP program) and a $146,000 decrease in toxicology expenses (2NTX-99 program).
• General and Administrative (G&A): G&A expenses dropped significantly by approximately $736,000 (61%) to $462,000. The primary driver was a $612,000 reduction in stock-based compensation, alongside decreases in professional fees and occupancy costs.
• Interest Income: Interest income fell from $149,436 in Q1 2008 to $14,686 in Q1 2009 due to substantially lower cash balances.
• Liquidity: Cash and cash equivalents decreased by $1.89 million from $5.5 million at December 31, 2008, to $3.6 million at March 31, 2009.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

Management believes current capital resources ($3.6 million) are sufficient to fund operations through the third quarter of 2009, contingent on patient enrollment rates. The company plans to initiate a 30-patient Phase IIb study for CD-NP following the release of an FDA clinical hold. Future funding will be required to complete this trial and subsequent larger Phase IIb studies.

Management Commentary and Unusual Items

• FDA Clinical Hold: In March 2009, the FDA placed a clinical hold on the CD-NP program, requesting additional data on the Phase IIa trial and modifications to the Investigator Brochure. Nile submitted a response in April and expects a decision by the end of May 2009.
• Program Termination: The company terminated the 2NTX-99 program effective April 16, 2009, recording a one-time impairment charge of $48,500 for unamortized patent costs.
• Cost Savings Measures: As of May 8, 2009 (subsequent event), the company laid off administrative and development employees, including the Vice President of Development. This resulted in the cancellation of unvested options for 471,466 shares.

Risks and Contingencies

• Going Concern: The filing states there is substantial doubt about the company's ability to continue as a going concern. Continued operations depend on obtaining further long-term financing, successful product development, and market acceptance.
• Capital Needs: The company has no product revenue and expects to incur substantial losses. Failure to raise additional funds could force the company to delay, scale back, or eliminate R&D programs or wind down operations.
• Dilution: Future equity financing will likely result in significant dilution to current stockholders.

Investor Verification Checklist

• Verify the status of the FDA clinical hold on the CD-NP program and the timeline for its resolution.
• Confirm the company's cash runway and the specific milestones required to trigger the need for additional financing before Q3 2009.
• Review the impact of recent layoffs on the execution of the planned 30-patient Phase IIb study.
• Assess the terms of the license agreements with Mayo Clinic, specifically regarding future milestone payments and equity issuance obligations.
• Monitor the company's ability to secure capital in the current economic environment given the "substantial doubt" regarding going concern status.